Latest & greatest articles for montelukast

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on montelukast or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on montelukast and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for montelukast

1. Montelukast as an episodic modifier for acute viral bronchiolitis: a randomized trial. (PubMed)

Montelukast as an episodic modifier for acute viral bronchiolitis: a randomized trial. This study was designed to evaluate the effect of once-daily montelukast therapy on the clinical progress and the cytokine profile of patients with acute viral bronchiolitis. A randomized, double-blind, placebo-controlled trial included 85 patients (mean age, 3.5 +/- 2.35 months), clinically diagnosed as first-episode acute bronchiolitis in addition to 10 healthy controls of matched age and sex. Patients were (...) randomly assigned to receive either montelukast (4-mg sachets; n = 47) or placebo (n = 38) daily from the time of admission until discharge. The primary outcome measure was the length of hospital stay (LOS), and clinical severity scores (CSs) and changes in plasma levels of interferon gamma and interleukin-4 were secondary outcomes. LOS for the montelukast group was found to be significantly lower than that of the placebo group (p < 0.05). This effect was also found at nonsignificant levels among

Full Text available with Trip Pro

2010 Allergy and Asthma Proceedings Controlled trial quality: predicted high

2. The role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with meta-analysis

The role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with meta-analysis The role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with meta-analysis The role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with meta-analysis Castro-Rodriguez JA, Rodrigo GJ CRD summary This review concluded (...) that inhaled corticosteroids led to less asthma exacerbations compared with montelukast for the prevention of asthma exacerbations in children with mild-to-moderate persistent asthma. Although there was uncertainty related to some aspects of the reporting of the review, the authors’ conclusions reflected the evidence presented and appear to be broadly reliable. Authors' objectives To assess the efficacy of inhaled corticosteroids and montelukast for the prevention of asthma exacerbations in children

2010 DARE.

3. Montelukast versus inhaled corticosteroids as monotherapy for prevention of asthma: which one is best?

Montelukast versus inhaled corticosteroids as monotherapy for prevention of asthma: which one is best? Montelukast versus inhaled corticosteroids as monotherapy for prevention of asthma: which one is best? Montelukast versus inhaled corticosteroids as monotherapy for prevention of asthma: which one is best? Miceli Sopo S, Onesimo R, Radzik D, Scala G, Cardinale F CRD summary The review’s conclusion appeared to be that inhaled corticosteroids were effective and should be the first choice (...) treatment for paediatric persistent asthma, with montelukast as a possible alternative in children unable to use inhaled corticosteroids. The reliability of these conclusions is unclear given numerous limitations in the conduct and reporting of the review. Authors' objectives To compare the effectiveness of montelukast compared with inhaled corticosteroids as monotherapy in the prevention of asthma in children. Searching MEDLINE was searched (up to December 2008) for English-language papers. Search

2009 DARE.

4. Economic evaluation of quality-of-life improvement with second-generation antihistamines and montelukast in patients with allergic rhinitis

Economic evaluation of quality-of-life improvement with second-generation antihistamines and montelukast in patients with allergic rhinitis Economic evaluation of quality-of-life improvement with second-generation antihistamines and montelukast in patients with allergic rhinitis Economic evaluation of quality-of-life improvement with second-generation antihistamines and montelukast in patients with allergic rhinitis Saverno KR, Seal B, Goodman MJ, Meyer K Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of several second-generation antihistamines (levocetirizine, desloratadine, and fexofenadine) and montelukast for uncomplicated allergic rhinitis, focusing on improvements in quality

2009 NHS Economic Evaluation Database.

5. A meta-analysis of montelukast for recurrent wheeze in preschool children. (PubMed)

A meta-analysis of montelukast for recurrent wheeze in preschool children. There is conflicting evidence of the effectiveness of montelukast in preschool wheeze. A recent Cochrane review focused on its use in viral-induced wheeze; however, such subgroups are unlikely to exist in real life and change with time, recently highlighted in an international consensus report. We have therefore sought to investigate the effectiveness of montelukast in all children with preschool wheeze (viral-induced (...) and multiple-trigger wheeze). The PubMed, Cochrane Library, Ovid Medline and Ovid EMBASE were screened for randomised controlled trials (RCTs), examining the efficacy of montelukast compared with placebo in children with the recurrent preschool wheeze. The primary endpoint examined was frequency of wheezing episodes. Five trials containing 3960 patients with a preschool wheezing disorder were analysed. Meta-analyses of studies of intermittent montelukast showed no benefit in preventing episodes of wheeze

Full Text available with Trip Pro

2017 European journal of pediatrics

6. A Study Comparing Montelukast With Placebo in Children With Seasonal Allergic Rhinitis (0476-219)(COMPLETED)

A Study Comparing Montelukast With Placebo in Children With Seasonal Allergic Rhinitis (0476-219)(COMPLETED) A Study Comparing Montelukast With Placebo in Children With Seasonal Allergic Rhinitis (0476-219)(COMPLETED) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. A Study Comparing Montelukast With Placebo in Children With Seasonal Allergic Rhinitis (0476-219)(COMPLETED) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00968149 Recruitment Status : Completed First Posted : August 28, 2009 Results

2009 Clinical Trials

7. Montelukast

Montelukast Top results for montelukast - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for montelukast The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

8. Effects of Montelukast in Asthmatic Children With and Without Food Allergy

Effects of Montelukast in Asthmatic Children With and Without Food Allergy Effects of Montelukast in Asthmatic Children With and Without Food Allergy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Effects (...) of Montelukast in Asthmatic Children With and Without Food Allergy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01618929 Recruitment Status : Completed First Posted : June 13, 2012 Last Update Posted : August 14, 2017 Sponsor: Hacettepe University Collaborator: Merck Sharp & Dohme Corp. Information

2012 Clinical Trials

9. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review

Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review Joos S, Miksch A, Szecsenyi J, Wieseler B, Grouven U, Kaiser T, Schneider A CRD summary The authors concluded that adding montelukast (...) to inhaled corticosteroids (ICS) improved control of mild to moderate asthma, and that salmeterol was at least as effective as montelukast as an add-on therapy, but that montelukast may be safer long term. These conclusions may require some caution in interpretation due to the scarcity of good quality data and heterogeneity between the studies. Authors' objectives To evaluate the medium to long-term use of montelukast as add-on therapy to inhaled corticosteroids (ICS) in adolescents and adults

2008 DARE.

10. [Cost effectiveness of treatment with salmeterol/fluticasone compared to montelukast for the control of persistent asthma in children]. (PubMed)

[Cost effectiveness of treatment with salmeterol/fluticasone compared to montelukast for the control of persistent asthma in children]. To assess the incremental cost-effectiveness of SFC compared with MON for the control of persistent asthma in children.We conducted an economic evaluation on a 12-week prospective randomized open-label parallel-group comparison of SFC versus MON in children with symptomatic asthma receiving inhaled corticosteroids and short-acting β2-agonists. Asthma-related

Full Text available with Trip Pro

2011 Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research Controlled trial quality: uncertain

11. A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. (PubMed)

A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. To compare the effects of addition of montelukast or salmeterol to inhaled corticosteroids (ICS) on the response to rescue beta2-agonist use after exercise-induced bronchoconstriction.A double-blind, placebo-controlled study was performed at 16 centers in the United States. Patients with asthma (n = 122, ages 15-58) whose symptoms were uncontrolled on Low-dose inhaled (...) fluticasone and who had a history of exercise-induced worsening of asthma were randomized to receive either montelukast (10 mg once daily), salmeterol (50microg twice daily), or placebo for 4 weeks. Standardized spirometry after exercise challenge and beta2-agonist rescue was performed at baseline, week 1 and 4.Maximum achievable forced expiratory volume in 1 s (FEV1) percent predicted after rescue beta2-agonist improved in the montelukast (+1.5%) and placebo (+1.2%) groups at 4 weeks, but diminished

2004 Respiratory medicine Controlled trial quality: uncertain

12. Clinical effect of montelukast sodium combined with inhaled corticosteroids in the treatment of OSAS children. (PubMed)

Clinical effect of montelukast sodium combined with inhaled corticosteroids in the treatment of OSAS children. This study was designed to investigate the clinical effect of montelukast sodium combined with inhaled corticosteroids in the treatment of children with obstructive sleep apnea syndrome (OSAS).One hundred ninety-five children were enrolled and divided into 3 groups: groups A, B, and C; the group A (oral use of montelukast sodium), group B (nasal spray of mometasone furoate), and group (...) C (oral use of montelukast sodium + nasal spray of mometasone furoate). Telephone questionnaire surveys were carried out. Polysomnography monitoring was performed and lateral x-ray radiographs of the cervical spine were taken before treatment and at 12 weeks after treatment. The improvement of clinical symptoms after treatment and its effective rate were analyzed. The difference in clinical characteristics between groups C1 and C2 was analyzed.In the 3 groups, clinical symptoms improved at 12

Full Text available with Trip Pro

2017 Medicine Controlled trial quality: uncertain

13. Montelukast Treatment of Acute Asthma Exacerbations in Children Aged 2 to 5 Years: A Randomized, Double-Blind, Placebo-Controlled Trial. (PubMed)

Montelukast Treatment of Acute Asthma Exacerbations in Children Aged 2 to 5 Years: A Randomized, Double-Blind, Placebo-Controlled Trial. Although montelukast has an established role in the management of chronic asthma in children, its efficacy in acute asthma exacerbations (AAEs) in children aged 2 to 5 years is not fully known. This study aimed to evaluate the effectiveness and safety of montelukast for treating AAE in children aged 2 to 5 years in China.In total, 120 Chinese children with AAE (...) , aged 2 to 5 years, were randomly divided into 2 groups, each with 60 patients. All patients received either montelukast or placebo along with standard therapy for acute asthma between January 2011 and December 2015. The outcome measurements included the difference in peak expiratory flow and lung function improvements, as well as adverse events.A total of 117 patients completed the study. Montelukast showed no greater effectiveness than did placebo in increasing the peak expiratory flow during

2017 Pediatric Emergency Care Controlled trial quality: predicted high

14. A randomized placebo-controlled trial of traditional Chinese medicine as an add-on therapy to oral montelukast in the treatment of mild persistent asthma in children. (PubMed)

A randomized placebo-controlled trial of traditional Chinese medicine as an add-on therapy to oral montelukast in the treatment of mild persistent asthma in children. Traditional Chinese medicine are commonly used for treatment of asthma. However, there are only very limited data about its efficacy in children. Therefore, we aimed to determine the efficacy of augmented Yu Ping Feng San (aYPFS) as an add-on to oral montelukast compared with montelukast alone for treatment of mild persistent (...) asthma in children.A single centre, placebo-controlled, double-blinded, randomized control trial was carried out. Participants with age 6-18 years who had mild persistent asthma were randomized according to random number list to receive either aYPFS plus montelukast for 24 weeks or placebo plus montelukast for 24 weeks. Primary outcome measure was lung function parameters. Secondary outcome measures were Asthma Control Test™ (ACT™) and Paediatric Allergic Disease Quality of Life Questionnaire (PADQLQ

2016 Complementary Therapies In Medicine Controlled trial quality: predicted high

15. Addition of Montelukast to Low-Dose Inhaled Corticosteroid Leads to Fewer Exacerbations in Older Patients Than Medium-Dose Inhaled Corticosteroid Monotherapy. (PubMed)

Addition of Montelukast to Low-Dose Inhaled Corticosteroid Leads to Fewer Exacerbations in Older Patients Than Medium-Dose Inhaled Corticosteroid Monotherapy. There have been few reports regarding the efficacy of antiasthmatics in older patients. To compare the efficacy of the addition of montelukast to low-dose inhaled budesonide (MON-400BUD) versus increasing the dose of inhaled steroid (800BUD) on asthma control in older asthmatics.A randomized, open-label, parallel-designed trial

Full Text available with Trip Pro

2015 Allergy, asthma & immunology research Controlled trial quality: uncertain

16. Montelukast as an add-on treatment in steroid dependant nephrotic syndrome, randomised-controlled trial. (PubMed)

Montelukast as an add-on treatment in steroid dependant nephrotic syndrome, randomised-controlled trial. The underlying mechanisms of nephrotic syndrome (NS) are still under debate and the need for more effective and less toxic treatment is challenging. We aimed to evaluate the efficacy of montelukast, a leukotriene receptor antagonist as an add-on therapy, and to explore the leukotriene (LT) biology in steroid-dependent nephrotic syndrome (SDNS).A randomized controlled trial was conducted (...) including 32 patients with SDNS who were randomly assigned to receive standard steroid treatment only [low-dose steroid (LDS) group] or standard steroid therapy plus montelukast (Montelukast group). Urine protein/creatinine ratio, serum albumin, creatinine, cholesterol, and plasma LTs (LTB4/C4/D4/E4) were evaluated in all patients before and after treatment.After treatment, both groups showed a significant decrease of LTB4 and LTC4/D4/E4. Further, the Montelukast group showed a significant decrease

2016 Journal of nephrology Controlled trial quality: uncertain

17. Neuropsychiatric adverse drug reactions in children initiated on montelukast in real-life practice. (PubMed)

Neuropsychiatric adverse drug reactions in children initiated on montelukast in real-life practice. Although montelukast is generally well tolerated, postmarketing studies have reported serious neuropsychiatric adverse drug reactions (ADRs) leading to a United States Food and Drug Administration black box warning. The objective of this study was to determine the incidence of neuropsychiatric ADRs leading to discontinuation of montelukast in asthmatic children.We conducted a retrospective cohort (...) study in children aged 1-17 years initiated on montelukast. In a nested cohort study, children initiated on montelukast as monotherapy or adjunct therapy to inhaled corticosteroids (ICS) were matched to those initiated on ICS monotherapy. A non-leading parental interview served to ascertain the occurrence of any ADRs with any asthma medication, and circumstances related to, and evolution of, the event.Out of the 106 participants who initiated montelukast, most were male (58%), Caucasian (62

Full Text available with Trip Pro

2017 European Respiratory Journal

18. Clinical effect of treating secondary asthma attacks of children Mycoplasma pneumoniae with combined therapy of montelukast and azithromycin. (PubMed)

Clinical effect of treating secondary asthma attacks of children Mycoplasma pneumoniae with combined therapy of montelukast and azithromycin. To discuss the clinical effects of treating secondary asthma attacks of children Mycoplasma pneumoniae with combined therapy of montelukast and azithromycin.96 children patients diagnosed with secondary asthma attacks of Mycoplasma pneumonia were enrolled in this study. They were randomly divided into two groups: the control group (n=49 (...) ) and the observation group (n=47). Patients in the control group received combined therapy using azithromycin and bronchodilators or glucocorticoid, and patients in the observation group received a combined therapy of montelukast, azithromycin and bronchodilators or glucocorticoid. The lung function indexes, T lymphocyte subpopulation, cytokines levels, positive rate of lgG and lgM, asthma control rate and recurrence rate were compared between groups before and after treatment.The levels of V-T, t-PTEF/t-E, MTIF

2017 European review for medical and pharmacological sciences

19. Montelukast and budesonide combination for children with chronic cough-variant asthma. (PubMed)

Montelukast and budesonide combination for children with chronic cough-variant asthma. This study investigated the effectiveness and safety of montelukast combined budesonide (MCB) treatment for children with chronic cough-variant asthma (CCVA).In total, 82 cases of children with CCVA, aged 4 to 11 years were included in this study. All cases received either MCB or budesonide alone between May 2015 and April 2017. The primary outcome was lung function, measured by the peak expiratory flow rates

Full Text available with Trip Pro

2018 Medicine

20. Randomised controlled trial: Montelukast potentially efficacious in children with non-severe obstructive sleep apnoea in the short term

Randomised controlled trial: Montelukast potentially efficacious in children with non-severe obstructive sleep apnoea in the short term Montelukast potentially efficacious in children with non-severe obstructive sleep apnoea in the short term | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Montelukast potentially efficacious in children with non-severe obstructive sleep apnoea in the short term Article Text Therapeutics Randomised

2013 Evidence-Based Medicine (Requires free registration)